Blood pressure control in hypertensive patients with left ventricular hypertrophy. The VIIDA study;Control de las cifras de presión arterial en los pacientes hipertensos con hipertrofia ventricular: Estudio VIIDA

Revista Espanola de Cardiologia

Volumn 60, Issue 12, 2007, Pages 1257-1263

  Bertomeu, Vicente ^a   Fácila Rubio, Lorenzo ^b   González Juanatey, José R ^c   Cea Calvo, Luis ^d   Aznar, Joaquín ^e   Mazónc, Pilar ^c   Gonzáleza, Vicente Bertomeu ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d Medical affairs Merck sharp and Dohme ltd   (Spain)

^e Hospital Provincial Nuestra Señora de Gracia   (Spain)

Author keywords

Blood pressure control; Hypertension; Left ventricular hypertrophy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; SEIZURE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 37349072934     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13113931     Document Type: Article

References (20)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
3. Collins OR, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. En: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell; 1994. p. 1156-64.
4. González-Juanatey JR, Ezquerra EA, Vidal JV, Caro JL, Acuna JG, Maqueda IG. Impacto de la hipertensión en las cardiopatías en España. Estudio Cardiotens 1999. Rev Esp Cardiol. 2001;54:139-49.
5. González-Juanatey JR, Alegría EE, Maria García AJ, González MI, Vicente LJ. Impacto de la diabetes en las enfermedades cardíacas en España. Estudio CARDIOTENS 1999. Med Clin (Barc). 2001;116:686-91.
6. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol. 1998;31:383-90.
7. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-93.
8. Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlof B, Smith G, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol. 2001;87:54-60.
9. Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. J Hum Hypertens. 2004;18:403-9.
10. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
11. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74:714-9.
12. Lozano JV, Redon J, Cea-Calvo L, Fernández-Pérez C, Navarro J, Bonet A, et al. Estimación del riesgo de un primer ictus en la población hipertensa española en atención primaria. Estudio ERIC-HTA. Med Clin (Barc). 2005;125:247-51.
13. Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension. 2005;45:1125-30.
14. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9.
15. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.
16. Lozano JV, Redon J, Cea-Calvo L, Fernández-Pérez C, Navarro J, Bonet A, et al. Hipertrofia ventricular izquierda en la población hipertensa española. Estudio ERIC-HTA. Rev Esp Cardiol. 2006;59:136-42.
17. Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension. 2001;38:809-14.
18. Andrade SE, Gurwitz JH, Field TS, Kelleher M, Majumdar SR, Reed G, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10:481-6.
19. Greenberg JD, Tiwari A, Rajan M, Miller D, Natarajan S, Pogach L. Determinants of sustained uncontrolled blood pressure in a national cohort of persons with diabetes. Am J Hypertens. 2006;19:161-9.
20. Ruilope LM. Long-term protection in at-risk hypertensive patients - a role for nifedipine GITS? Blood Press. 2002;11:106-9.